jueves, 6 de mayo de 2021

FDA Approves ZYNLONTA (Loncastuximab Tesirine-lpyl) for the Treatment of Adult Patients with Elapsed or Refractory Large B-Cell Lymphoma after Two or More Lines of Systemic Therapy

label

No hay comentarios:

Publicar un comentario